News

NEO100-01 Meets Primary End Point, Supporting Further Development in IDH1-Mutant Glioma

08/31/2026

Emily Estrada

Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...

Topline results from the phase...

08/31/2026

Oncology

News

Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma

07/21/2026

Emily Estrada

Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...

Updated findings from the phase...

07/21/2026

Oncology

News

Dose-Escalation Study Supports Phase 2 Development of BMS-986205 Plus Radiotherapy and Nivolumab in Glioblastoma

07/09/2026

Stephanie Holland

Results from a phase 1 trial demonstrated that radiotherapy plus nivolumab and the IDO1 inhibitor BMS-986205 was generally well tolerated in patients with newly diagnosed IDH-wild-type glioblastoma, establishing a recommended phase 2 dose for...

Results from a phase 1 trial...

07/09/2026

Oncology

News

Radiotherapy and Temozolomide Produce Comparable Long-Term Outcomes in High-Risk Low-Grade Glioma

07/07/2026

Stephanie Holland

Long-term follow-up of a phase 3 trial showed that initial treatment with either radiotherapy or dose-dense temozolomide produced comparable survival outcomes in patients with clinically high-risk low-grade glioma, while molecular...

Long-term follow-up of a phase 3...

07/07/2026

Oncology

News

MRI-Guided Adaptive Radiotherapy Enables Margin Reduction in Adult Patients With Glioblastoma

06/30/2026

Emily Estrada

Results from the phase 2 UNITED trial demonstrated that MRI-guided adaptive radiotherapy with reduced treatment margins was associated with a low rate of marginal failure in adult patients with glioblastoma.

Results from the phase 2 UNITED...

06/30/2026

Oncology

News

WT1 Peptide Vaccine Demonstrates Immune Activity in Pediatric High-Grade Gliomas

06/30/2026

Emily Estrada

Results from a phase 1/2 study demonstrated that a Wilms' tumor gene 1 (WT1) peptide vaccine is well tolerated and elicited immune responses associated with improved survival among pediatric patients with high-grade gliomas.

Results from a phase 1/2 study...

06/30/2026

Oncology

News

Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma

06/05/2026

Emily Estrada

Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.

Results from a phase 2 study...

06/05/2026

Oncology

News

Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma

06/05/2026

Emily Estrada

Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.

Results from a phase 2 study...

06/05/2026

Oncology

News

ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma

06/05/2026

Emily Estrada

Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.

Results from a phase 2 trial...

06/05/2026

Oncology

News

ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma

06/05/2026

Emily Estrada

Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.

Results from a phase 2 trial...

06/05/2026

Oncology

Recent News

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology

News

Tarlatamab Plus Durvalumab Improves Survival as First-Line Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

09/15/2026

Emily Estrada

Topline results from the phase 3 DeLLphi-305 trial showed that adding tarlatamab to durvalumab significantly improved overall and progression-free survival compared with durvalumab alone as first-line maintenance therapy for patients with...

Topline results from the phase 3...

09/15/2026

Oncology

News

GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia

09/15/2026

Emily Estrada

Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...

Real-world findings associated...

09/15/2026

Oncology

News

Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia

09/15/2026

Emily Estrada

Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...

Extended results from the phase...

09/15/2026

Oncology